Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside ... technological advances, new products and patents attained by competitors; challenges inherent in new product development ...

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing Consortium aimed at pioneering new advances in how medicines are produced.

Robert F. Kennedy Jr., President Trump’s nominee to be health secretary, would have oversight power over the vaccine’s maker, Merck, if confirmed. By Christina Jewett and Sheryl Gay Stolberg ...

In separate presentations, the CEOs of Bristol Myers Squibb, Pfizer and Merck laid out their plans ... Bristol’s buyout of Celgene, will face a new slate of generics in March and then a full ...

Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target to $119.00. Discover outperforming stocks and invest ...

In an interview on CNBC’s Mad Money, Robert Davis said Merck’s (MRK) current pipeline is the most diversified it has been in recent history. “We’re not just a Keytruda company, we’re an ...

Kennedy Jr. played an instrumental role in organizing mass litigation against drugmaker Merck over its Gardasil ... in San Francisco and Mike Spector in New York; Additional reporting by Michael ...

Merck CEO Rob Davis told CNBC's Jim Cramer that there's more to the pharmaceutical giant than its lucrative cancer drug, Keytruda, and he described other ventures in its portfolio. "Keytruda has ...

a law firm suing Merck over claims that the pharmaceutical company failed to properly warn consumers about risks from its HPV vaccine, Gardasil, according to new filings with the Office of ...